Evidence map›Paper›PMID 35871649›Full record

ArticleBMC gastroenterology2022

Current status of and barriers to the treatment of advanced-stage liver cancer in China: a questionnaire-based study from the perspective of doctors.

Qiaoxin Wei, Haiyang Zhou, Xinhui Hou, Xiaoping Liu, Sisi Chen, Xueying Huang, Yu Chen, Mei Liu, Zhongping Duan

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qiaoxin Wei *Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China.
Haiyang Zhou *Beijing iGandan Foundation, 103-5C16-1, 1F, Building 1, No. 16, South Third Ring West Road, Fengtai District, Beijing, 100069, China.
Xinhui HouBeijing iGandan Foundation, 103-5C16-1, 1F, Building 1, No. 16, South Third Ring West Road, Fengtai District, Beijing, 100069, China.
Xiaoping LiuBeijing iGandan Foundation, 103-5C16-1, 1F, Building 1, No. 16, South Third Ring West Road, Fengtai District, Beijing, 100069, China.
Sisi ChenDepartment of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China.
Xueying HuangDepartment of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China.
Yu ChenFourth Department of Hepatology Center, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China.
Mei LiuDepartment of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China. liumei@ccmu.edu.cn.
Zhongping DuanFourth Department of Hepatology Center, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China. duan@ccmu.edu.cn.
Capital Medical University · CNBeijing Fengtai Hospital · CNBeijing YouAn Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver cancer is a severe public health problem worldwide, and it creates a relatively higher disease burden in China than in the Western world. Despite achieving notable progress in China, potential differences in some aspects of medical services for liver cancer may persist across different regions and hospitals. This warrants serious consideration of the actual status of and barriers to liver cancer treatment. We intended to explore the present status of and obstacles in liver cancer treatment especially for advanced-stage liver cancer.

methodsIn February 2021, a national multicenter cross-sectional study was conducted among 1500 doctors from 31 provinces of mainland China using a self-administered online questionnaire. Participants completed the questionnaire about their general information, perspectives on the current status of liver cancer treatment, and expectations for future treatment. Chi-square and logistic regression analyses were performed to explore the differences associated with the regions, doctors' professional ranks, and hospital levels.

resultsTreatment conditions, medications, and treatment strategies were inconsistent across different economic regions and hospital of different levels. With respect to obstacles in treatment, 76.6% of the doctors were unsatisfied with the current treatment for liver cancer. Important factors that influenced their satisfaction with the treatment for liver cancer included early diagnosis and the disclosure of true conditions to patients.

conclusionsThere persists differences in the treatment of liver cancer in China, besides barriers to treatment. More attention should be paid to the detection and treatment of liver cancer and the propagation of novel progress among doctors in underdeveloped areas.

Indexed as

Liver NeoplasmsPhysiciansChinaCross-Sectional StudiesHumansSurveys and QuestionnairesBarriersCross-sectional studyDoctor satisfactionLiver cancerQuestionnaires

Identifiers

PMID35871649
PMCPMC9310466
OpenAlexW4286817203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.